Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Streptococcal Disease
Vaccine Against Group A Strep Infections Approved For Phase I/II Clinical Trial
April 11th, 2001
ID Biomedical Corp. announced on March 21, 2001, that it has been granted permission by the Therapeutic Products Program of Health Canada to conduct a Phase I/II clinical trial of StreptAvaxTM, a vaccine for the prevention of infections caused by group A Streptococcus. StreptAvax is the only vaccine of its kind being tested in human clinical trials. It is a multivalent recombinant vaccine developed to cover 26 serotypes of group A Streptococcus. According to data obtained from the U.S. Centers for Disease Control and Prevention (CDC), these serotypes are believed to be responsible for causing the vast majority of group A...
Source: Vaccine Weekly (2001-04-11)
|
